Korlym® (mifepristone) 300 mg Tablets available outside the United States through Idis
Korlym is available to patients globally (outside the United States) through Idis, a Managed Access Company.
- On a named-patient basis patients can be prescribed investigational or approved drugs prior to commercial launch in their respective countries
- Corcept is partnering with Idis to ensure regulatory compliance and ethical access to Korlym, a treatment option for patients with Cushing’s syndrom
Korlym is a prescription medicine licensed in the United States to treat adult patients with Cushing’s syndrome who have high blood sugar (hyperglycemia) caused by high cortisol levels and have failed surgery or cannot have surgery. Korlym is a competitive antagonist of the glucocorticoid receptor, which is the primary target of excess cortisol.
Licensed healthcare professionals outside the United States should direct all international product inquiries to:
Sean Maduck, Senior Vice President, Commercial
Tel: 1 (650) 688-2819
Indications and Usage
Korlym® (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Important Limitations of Use
Do not use for the treatment of type 2 diabetes mellitus unrelated to endogenous Cushing's syndrome.